## Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 8-K

ELITE PHARMACEUTICALS INC /DE/ Form 8-K February 03, 2003

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 31, 2003

ELITE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

State or other jurisdiction of incorporation: Delaware

Commission File No.: 333-45241

I.R.S. Employer Identification No.: 22-3542636

Address of principal executive offices 165 Ludlow Avenue Northvale, New Jersey 07647

Registrant's telephone number, including area code: 201 750-2646

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

99.1 Letter to Shareholders of Elite

## Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 8-K

99.2 Letter to Warrantholders of Elite

ITEM 9. REGULATION FD DISCLOSURE

Pursuant to Regulation FD, Elite hereby furnishes the information contained in Exhibit 99.1 and Exhibit 99.2 attached hereto, which are incorporated herein by this reference.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 3, 2003

ELITE PHARMACEUTICALS, INC.

/s/ Atul M. Mehta By:

Atul M. Mehta President

-2-

EXHIBIT INDEX

Exhibit No.	Description
99.1	Letter to Shareholders
99.2	Letter to Warrantholders